Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed its Keytruda could produce. More: ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats
read moreEven before it launched, Novartis’ Kisqali was living in the shadow of classmate Ibrance, and it has been ever since. But with its latest data set, Kisqali now has an advantage the Pfizer blockbuster can’t boast. More: ASCO: Novartis' Kisqali
read moreJohnson & Johnson’s Erleada may be the follow-up to blockbuster Zytiga, but it’s also ready to go where its predecessor hasn’t gone before. More: ASCO: J&J pads case for new Erleada use with prostate cancer survival data Source: fierce
read moreAs the year’s largest cancer confab, the American Society of Clinical Oncology annual meeting features more new data than any one person could hope to absorb—and more than we could hope to cover. We’re breaking down the highlights below to
read moreWhen Mitsubishi Tanabe’s Radicava got its nod from the FDA in 2016, it marked a turning point for ALS patients after 20 years without a new treatment on the market. But despite the hype—and with the drug’s eye-popping price tag
read moreTeva had a rough week after settling an opioid case for $85 million last weekend. Two analysts downgraded the company, and shares hit a 19-year low. More: Teva shares hit 19-year low after opioid settlement, analyst downgrades Source: fierce
read more© 1994 - 2025 B.M. Pharmaceuticals